Recommended for the treatment of stent restenosis, small vessel disease and branch lesions.
Clinical evidences support in primary coronary artery lesions such as macrovascular lesions.
Materials
Improved PEBAX guarantees higher flexibility and enhanced crossability
Drug
Loaded Paclitaxel inhibit restenosis continuously.
Drug Coating
Coated with Active Pharmaceutical Ingredients grade urea, provide better biocompatibility, facilitate drug releasing effectively.
Delivery system
Spiral cut hypotube design, strengthen the transition section, bring optimized deliverability for transition.